This paper explores several critical assumptions and methodological issues arising in cost-effectiveness analyses of genetic screening strategies in the reproductive setting.
Seven issues that arose in the development of a decision analysis of alternative strategies for cystic fibrosis carrier screening are discussed.
Each of these issues required a choice in technique.
The presentations of these analyses frequently mask underlying assumptions and methodological choices.
Often there is no best choice.
In the case of genetic screening in the reproductive setting, these underlying issues often touch on deeply felt human values.
Space limitations for published paper often preclude explaining such choices in detail ; yet these decisions determine the way the results should be interpreted.
Those who develop these analyses need to make sure that the implications of important assumptions are understood by the clinicians who will use them.
At the same time, clinicians need to enhance their understanding of what these models truly mean and how they address underlying clinical, ethical, and economic issues.
Mots-clés Pascal : Mucoviscidose, Dépistage, Stratégie, Analyse décision, Analyse coût efficacité, Economie santé, Homme, Prénatal, Parent, Appareil respiratoire pathologie, Appareil digestif pathologie, Pancréas pathologie, Maladie héréditaire, Métabolisme pathologie
Mots-clés Pascal anglais : Cystic fibrosis, Medical screening, Strategy, Decision analysis, Cost efficiency analysis, Health economy, Human, Prenatal, Parent, Respiratory disease, Digestive diseases, Pancreatic disease, Genetic disease, Metabolic diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0273299
Code Inist : 002B30A03B. Création : 199608.